Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piramal R&D Spinoff Gets Name, Seeks Foreign Partner

This article was originally published in PharmAsia News

Executive Summary

Piramal Healthcare's recently spun-off research and development arm has been named Piramal Life Sciences as it seeks a foreign partner. The new partner, which would have a 10 percent equity in the new company, is expected to be a multinational drug maker with a strong emphasis on drug discovery. The R&D firm has 14 compounds in its research pipeline, four of them undergoing clinical trials, and it already has discovery and development agreements with Lilly, Merck and other major drug research companies. (Click here for more

You may also be interested in...



Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis

In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel